Gibson Dunn Represented Cytokinetics in $805 Million Offering of Common Stock
In a public offering of 11,338,028 shares of common stock, including the full exercise of the underwriters’ option to buy an additional 1,478,873 shares, Gibson Dunn represented Cytokinetics, Incorporated. Cytokinetics received total gross proceeds from the offering of about $805 million. The offering’s joint book-running managers were Morgan Stanley, Goldman Sachs & Co. LLC, J.P. Morgan, and Jefferies.